British Columbia Investment Management Corp Arvinas, Inc. Transaction History

British Columbia Investment Management Corp

$16 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$60.27 - $81.57 $548,517 - $742,368	-9,101 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$65.85 - $96.21 $240,484 - $351,358	-3,652 Reduced 28.64%	9,101 $748,000
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $933,519 - $1.38 Million	12,753 New	12,753 $1.05 Million
Q4 2019 Feb 12, 2020	SELL	$15.39 - $44.38 $253,935 - $732,270	-16,500 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $355,575 - $455,565	16,500 New	16,500 $356,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

Vanguard Group Inc Valley Forge, PA

7.01M
Shares

$129 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.73M
Shares

$124 Million
7.19% of portfolio
Black Rock Inc. New York, NY

6.26M
Shares

$116 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.85M
Shares

$71.2 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

2.78M
Shares

$51.4 Million
1.09% of portfolio

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $983M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.

Account